Newsroom

Welcome to the Symplmed Newsroom. In this space, you will find all you need to know about Symplmed. For more information, follow us on Twitter at @symplmed.

February 24, 2016

Symplmed Pharmaceuticals Announces FDA Orange Book Listing for Two Prestalia Patents

Cincinnati, OH–February 24, 2016 – Symplmed Pharmaceuticals announced today that two patents covering Prestalia® (perindopril arginine and amlodipine besylate) are now listed in the U.S. Food and Drug Administration’s (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The two Prestalia patents (6696481 and 7846961) offer product exclusivity until 2029.


October 1, 2015

Symplmed and PuraCap Pharmaceutical LLC partner to distribute new EpiCeram‑L™ Lip Care through DyrctAxess Technology

Cincinnati, OH–October 1, 2015 – Symplmed announced today that it has entered into an agreement with PuraCap® Pharmaceutical LLC to distribute a new product, EpiCeram-L™ Lip Care, through Symplmed’s patented DyrctAxess technology. The program is designed to provide physicians with easy access to PuraCap’s growing portfolio of dermatology products.


September 10, 2015

Symplmed Launches Goal is Control Challenge to Motivate Patients to Reach and Maintain Blood Pressure Goals

Symplmed Pharmaceuticals, manufacturer of Prestalia® (perindopril arginine and amlodipine besylate), today announced the launch of the Goal is Control Challenge to motivate patients living with high blood pressure and reward them for getting their blood pressure under control.


July 9, 2015

Symplmed Launches Prestalia® for Treatment of Hypertension

Symplmed Pharmaceuticals today announced that Prestalia® (perindopril arginine and amlodipine besylate) tablets are now available by prescription in the United States.


April 2, 2015

#50Startups: Symplmed, Working to Streamline Healthcare

As featured in BendTECH, Symplmed works to reduce friction for patients and physicians dealing with chronic conditions like hypertension. They create new medicines, tools, and technology to simplify treatments – and deliver the prescriptions and equipment needed directly to manage care more efficiently.


January 26, 2015

Symplmed announces FDA approval of Prestalia® for treatment of hypertension

Symplmed Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Prestalia® (perindopril arginine and amlodipine) tablets, licensed from Servier (Suresnes, France), for the treatment of hypertension.


January 7, 2015

Symplmed brings VAYA Pharma products into DyrctAxess Technology®

Symplmed Pharmaceuticals announced today that it has entered into an agreement with VAYA Pharma to distribute its medical food products — Vayarin®, Vayacog® and Vayarol® — through VAYA-Direct. The patient membership program, powered by Symplmed’s patented DyrctAxess technology, will provide prescribers and patients with a guaranteed price of $49.50 or less for each of VAYA’s products at the recommended daily dose as prescribed by physicians. VAYA-Direct will also accept insurance plans and provide delivery right to a patient’s home, as well as prompt refills.


July 18, 2014

Symplmed Completes Ownership of Perindopril Franchise with Acquisition of ACEON®

Symplmed announced today that it has acquired U.S. rights to ACEON® (perindopril erbumine tablets), an angiotensin converting enzyme (ACE) inhibitor approved to treat patients with high blood pressure (hypertension) and reduce the risk of heart attack in patients with stable coronary artery disease. This acquisition completes Symplmed’s ownership of the perindopril franchise in the United States.


June 17, 2014

FDA Accepts New Drug Application for Symplmed’s Prestalia® for the Treatment of Hypertension

Symplmed announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for investigational drug Prestalia®, the first single-pill, fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate for the treatment of hypertension in the U.S. Symplmed filed the application under section 505(b)(2) consistent with FDA’s guidance. The Prescription Drug User Fee Act (PDUFA) goal date for Prestalia is January 21, 2015.


January 13, 2014

Symplmed and Next IT Partner to Offer Transformative Virtual Health Assistant Powered by Alme for Healthcare

SPOKANE, Wash. — (BUSINESS WIRE)—Next IT, developer of Alme, the world's most trusted virtual assistant platform, today announced a new partnership with Symplmed Pharmaceuticals LLC, a unique pharmaceutical company poised to simplify the prescribing and administration of essential medications through its patent pending technology, DyrctAxess. The two companies plan to launch a virtual health assistant, powered by the advanced Alme for Healthcare platform to empower clinicians and patients to achieve better clinical outcomes.